Reduced central serotonergic activity in mania: implications for the relationship between depression and mania.
D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D003863:Depression / Q000134:cerebrospinal fluid / Q000188:drug therapy; D004195:Disease Models, Animal; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007099:Imipramine / Q000494:pharmacology / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011339:Probenecid; D012701:Serotonin / Q000378:metabolism*; D014364:Tryptophan / Q000134:cerebrospinal fluid / Q000627:therapeutic use
D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D010649:Phenylalanine; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; D008094:Lithium; D007099:Imipramine; D011339:Probenecid; D008784:Methysergide